FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * FROM STEPHEN				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ Officer (give title below)					
(Clast) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 10/04/2021											
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned					
(Instr. 3) Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year	if Co	Code (Instr. 8)		(A) or	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		ollowing	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
				(World Buy, 1 ca		Code	V	Amour	(A) or (D)	Price	(msu. 5 u			or Indirect (I) (Instr. 4)	
Common Stock 10/04/2021				$F^{(1)}$ 249 D ${}^{\$}_{2.01}$ 68,542			D								
Reminder:	Report on a s	separate line fo	r each class of secur	ities beneficially of			Pers cont the t	ons wi tained i form di	no responding this for splays a	rm are curre	e not requ ntly valid	OMB con	formation spond unle trol numbe	ess	C 1474 (9-02)
1. Title of	2	3. Transaction		e.g., puts, calls, v	5.	ints, op					itle and	8. Price of	9. Number	of 10.	11. Natu
	Conversion or Exercise Price of Derivative Security	Date	Execution Da Year) any	te, if Transaction Code (Instr. 8)	Num of Der Sec Acc (A) Dis of (Ins	Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		Am Und Sec	ount of lerlying urities tr. 3 and	Derivative Security (Instr. 5)		Owner Form of Deriva Securit Direct or Indi	ship of Indire Benefici tive Ownersł (Instr. 4) (D) rect
				Code V	(A)	(D)	Date Exer	e rcisable	Expiration Date	n Title	Amount or Number of Shares				

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
FROM STEPHEN C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452	X		Executive Chairman					

Signatures

/s/ Sarah Romano, Attorney-in-Fact*	10/05/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 10/01/2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.